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The Comitt de l’tlntibiogramme de la Socittt 
FranGaise de Microbiologie was founded in 1980 by 
Professor Yves A. Chabbert, who served as chairman 
for two years. The original members were: J. E Acar, 
F. Bergogne-Berezin, R. Cluzel, A. Courtieu, P. 
Courvalin, J. Duval, C. Morel, A. Thabaut and 
M. Vtron. The chairmanship was passed in 1981 to 
Professor Roger Cluzel, who chaired the committee 
until 1995. The membership was enlarged by approxi- 
mately twenty to include microbiologists representative 
of both university-affiliated and non-affiliated hospitals, 
as well as a pharmacologist and a clinician. 
Since its origin, the CA-SFM has held two annual 
meetings, and has met three times annually since 1992. 
In addition, working parties have at times solicited the 
collaboration of experts outside its membership for 
participation in a project on a given subject. 
Until the present, the primary role of the CA-SFM 
has been to propose the breakpoints (concentrations 
and inhibition zone diameters) necessary for the 
determination of the susceptibility to new antibiotics. 
This has been carried out in several steps. 
The first step consists in the establishment, prior to 
approval for marketing (AMM), of the provisional 
values for each antibiotic, including: 
the distribution of minimal inhibitory concentra- 
tions (MICs) of several thousands of bacterial strains, 
susceptible as well as with biochemically and geneti- 
cally defined mechanisms of resistance, concerning 
antibiotics of the same class (evaluated in multicenter 
studies) ; 
the major pharmacokinetic parameters of the anti- 
biotic, considered according to its different routes of 
administration. 
clinical trials of the product. The critical diameters are 
determined by using a plot of concordance or, in the 
case of a poor correlation, with the aid of a scattergram, 
which reduces to a minimum the major errors of 
interpretation. The antibiotic load of the disks is 
selected ahead of time; it is usually identical within a 
family of antibiotics (e.g. 5 pg for the fluoro- 
quinolones) . 
The second step consists in the establishment of 
definitive breakpoints, taking into account the clinical 
results observed in the therapeutic data agreed upon by 
the AMM, and especially, the precise analysis of the 
documented clinical setbacks of bacteriologic origin. 
Individual opinions on the criteria required for 
determining breakpoints to separate susceptible, inter- 
mediate and resistant categories were pooled, and in 
1980 a formula was proposed. This formula, which 
includes different pharmacokinetic parameters, estab- 
lished a value for the weighted serum level available for 
the antibiotic which must be compared with the MIC 
histograms of the different bacterial subpopulations 
within a particular species. Ten years later the same 
type of formula was published by the BSAC. The 
importance accorded to the parameters involved varies 
f b m  one country to another: intrinsic activity of an 
antibiotic against a particular bacterial species; pharma- 
cokinetics and pharmacology related to doses and 
habitual routes of administration; and the biochemical 
and genetic data that characterize low- or high-level 
resistance of particular strains. This leads to corres- 
ponding differences from one country to another in the 
published susceptibility and resistance standards. The 
guiding principles of the CA-SFM were published 
under the title ‘Definition and determination of in vitro 
antibiotic susceptibility breakpoints for bacteria in 
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and intermediate-resistant zones vary according to 
whether they are established by the National Com- 
mittee for Clinical Laboratory Standards (NCCLS), by 
the BSAC or by the CA-SFM. 
In certain cases, it was possible to consider a 
revision of these breakpoints for some products due to 
the appearance of a new mechanism of resistance or to 
a modification of the therapeutic data or the dosage 
prescribed, in conjunction with the pharmaceutical 
industry, whch was involved as often as necessary for 
reviewing the data and reaching a consensus. 
The CA-SFM also established a series of rules for 
the interpretation of the in vitro antibiotic susceptibpty 
tests (the antibiogramme), taking into account an in- 
depth knowledge of the accepted mechanisms of 
resistance and of the technical procedures for their 
detection. These rules of interpretation most often 
concern the different members of one family of 
antibiotics for which the mechanism of resistance is the 
same. The important principles of the interpretative 
reading of the in vitro antibiotic susceptibility tests (the 
antibiogramme) were developed by P. Courvalin. They 
are based upon the precise analysis of the phenotype of 
resistance observed in vitro for a given strain; this 
analysis allows for the deduction of the accepted 
mechanism of resistance involved, and in this way, for 
the necessary adjustments. This is especially important 
in the case of a characteristic of resistance that is poorly 
expressed in vitro, where the use of a product involving 
this characteristic will manifest in a therapeutic setback. 
One of the most significant practical examples of this 
interpretative reading, described in detail by J. Sirot, 
concerns the detection of the strains that produce 
extended-spectrum P-lactamases by the disk method. 
Since 1992, the CA-SFM has organized a working 
group for the purpose of revising the different 
techniques used for the determination of antibiotic 
sensitivity. This revision resulted in the precise recom- 
mendations that form the subject of one of the 
contributions to this supplement. 
Additionally, the CA-SFM has taken the initiative, 
in conjunction with the Agence Franqaise du Mkdica- 
ment, which is responsible for issuing the AMM, in 
establishing the antibacterial spectrum of the new 
antibiotics and in revising the oldest drug products and 
analyzing them by family, 
The integration of the clinical results, the bacterial 
spectrum and the data provided by the surveillance of 
resistance for a particular antibiotic permits the 
establishment of the 'clinical spectrum' of this anti- 
biotic. Thus, the bacterial species are dvided into four 
classes: usually susceptible, moderately susceptible, 
resistant and non-constantly susceptible. The latter class 
provides epidemiologic information on the prevalence 
of the resistant strains. Before being definitively 
adopted, the clinical spectrum is submitted for con- 
sideration to the Syndicat National de l'hdustrie 
Pharmaceutique or is discussed with representatives of 
the pharmaceutical industry. 
The recommendations of the CA-SFM have been 
published since 1980 in a communiqui. which is revised 
and updated annually. This communication is published 
in French and appears in the journal Pathologie Biologie, 
the Bulletin of the Socittt FranGaise de Microbiolozie and the 
Bulletin ofthe Contrde de Qualitt which is distributed to 
the analytic laboratories of medical biology. It is also 
distributed as part of the abstract publication for the 
annual meeting in Paris, the first week of December, 
entitled Re'union Interdisciplinaire de Chimiothtrapie Anti- 
Infectieuse (RICAI). The 1996 version of this com- 
munication is included as part of this supplement. 
Throughout the years, the CA-SFM has been 
invited to present its point of view at various 
international congresses, most recently at the European 
Congress of Clinical Microbiology and Infectious 
Diseases in 1989 and 1995, at the International 
Congress of Chemotherapy in 1993 and at the Biannual 
Conference on Anti-infective Drugs and Chemo- 
therapy in 1994. 
In the interests of international harmony, it is 
imperative that the CA-SFM reinforce its relations with 
the other national and international committees. This 
would allow for the dissemination of a 'pragmatic 
consensus' and the elimination of potentially discrepant 
interpretations of the same strain, resulting in epi- 
demiologic studies of a consistently high quality. 
